$AZN
Market Cap:
$AZN SEC Filings
| Filing | Filed On |
|---|---|
| TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO | 25 Apr 2022 |
| ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC | 19 Apr 2022 |
| TOTAL VOTING RIGHTS | 01 Apr 2022 |
| ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL | 29 Mar 2022 |
| EVUSHELD APPROVED IN THE EU FOR COVID-19 | 28 Mar 2022 |
| DIRECTOR/PDMR SHAREHOLDING | 25 Mar 2022 |
| UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA | 24 Mar 2022 |
| EVUSHELD POSITIVE EU CHMP OPINION | 24 Mar 2022 |
| NOTICE OF AGM | 23 Mar 2022 |
| FORM 6-K | 23 Mar 2022 |
| SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS | 17 Mar 2022 |
| UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS | 14 Mar 2022 |
| LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER | 14 Mar 2022 |
| DIRECTOR/PDMR SHAREHOLDING | 09 Mar 2022 |
| DIRECTOR/PDMR SHAREHOLDING | 07 Mar 2022 |
| DIRECTOR/PDMR SHAREHOLDING | 01 Mar 2022 |
| TOTAL VOTING RIGHTS | 01 Mar 2022 |
| ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 | 01 Mar 2022 |
| FILING OF FORM 20-F WITH SEC | 23 Feb 2022 |
| ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC | 22 Feb 2022 |
